Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL · Alpha
██.█% Sign up free to reveal

Spyre Therapeutics, Inc. (SYRE) AI Forecast

Our AI analyzed Spyre Therapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$SYRE Neutral Signal Full forecast available
Sign Up Free

Spyre Therapeutics, Inc. (SYRE) Stock Forecast Sept. 24, 2026

Spyre Therapeutics, Inc. (SYRE) AI Stock Price Forecast & Investment Analysis

Spyre Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Spyre Therapeutics, Inc. (SYRE) - Comprehensive Stock Analysis & Investment Research

Deep dive into Spyre Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Spyre Therapeutics, Inc. Investment Summary

When evaluating whether Spyre Therapeutics, Inc. (SYRE) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Spyre Therapeutics, Inc. (SYRE) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $8 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Spyre Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Spyre Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Spyre Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Spyre Therapeutics, Inc.

Sign Up Free
Corporate Identity

Spyre Therapeutics, Inc. (Stock Symbol: SYRE) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Spyre Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Spyre Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Spyre Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Spyre Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Spyre Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Spyre Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Spyre Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Spyre Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Spyre Therapeutics, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Spyre Therapeutics, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Spyre Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 18.53 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Spyre Therapeutics, Inc. (SYRE) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Spyre Therapeutics, Inc. stock analysis.

Deep dive into Spyre Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Spyre Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Spyre Therapeutics, Inc.:

P/B Ratio 7.06x
Market Cap $7.77B
EPS $-2.33
Book Value/Share $12.49
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Spyre Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Spyre Therapeutics, Inc.: An ROE of -16.3% indicates room for improvement in shareholder value creation.

ROE -16.3%
ROA -15.3%
ROIC -18.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Spyre Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Spyre Therapeutics, Inc.: A current ratio of 18.53 indicates strong liquidity.

Current Ratio 18.53x
D/E Ratio 0.07x
Financial Leverage 1.07x
Working Capital $1.11B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Spyre Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Spyre Therapeutics, Inc.:

Operating Cash Flow -$209M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Spyre Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Spyre Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Spyre Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Spyre Therapeutics, Inc.:

Income Statement
Operating Income -$201M
Net Income -$178M
R&D Expense $216M
Balance Sheet Highlights (USD millions)
Total Current Assets $1.17B (100.0% of assets)
Cash & Short-term Investments $162M (13.8% of assets)
Total Liabilities $72M (6.1% of assets)
Dividend & Shareholder Information
Shares Outstanding 88M

Latest Spyre Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Spyre Therapeutics, Inc. (SYRE) stock price and investment outlook.

📰 Loading...

Where SYRE sits on the market map

Explore the map →

Spyre Therapeutics, Inc. Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Spyre Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
SYRE ██% $7.77B x 7.1x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Spyre Therapeutics, Inc. Stock Forecast

How accurate are Spyre Therapeutics, Inc. stock predictions?

A per-ticker accuracy statistic for SYRE is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Spyre Therapeutics, Inc. stock price forecasts?

Our analysis considers Spyre Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Spyre Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Spyre Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Spyre Therapeutics, Inc. forecasts updated?

Spyre Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Spyre Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...